Systematic review with network meta-analysis: Comparative efficacy of oral nucleos(t)ide analogues for the prevention of chemotherapy-induced hepatitis B virus reactivation

Oncotarget

Volumn 7, Issue 21, 2016, Pages 30642-30658

  Zhang, Min Yue ^a   Zhu, Gui Qi ^b,c   Shi, Ke Qing ^b,c   Zheng, Ji Na ^b,c   Cheng, Zhang ^b,c   Zou, Zhuo Lin ^d   Huang, Hong Hui ^a   Chen, Fang Yuan ^a   Zheng, Ming Hua ^b,c  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b THE FIRST AFFILIATED HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

^c WENZHOU MEDICAL UNIVERSITY   (China)

^d Department of Stomatology The First Hospital of Jiaxing   (China)

Author keywords

Chemotherapy; Hepatitis B virus reactivation; Indirect comparison; Network meta analysis; Nucleos(t)ide analogues prophylaxis

Indexed keywords

ADEFOVIR; ANTINEOPLASTIC AGENT; ENTECAVIR; LAMIVUDINE; NUCLEOSIDE ANALOG; TELBIVUDINE; TENOFOVIR; ADENINE; ANTIVIRUS AGENT; GUANINE; PHOSPHONIC ACID DERIVATIVE; THYMIDINE;

ARTICLE; CANCER CHEMOTHERAPY; CAUSE OF DEATH; CHEMOTHERAPY INDUCED HEPATITIS B VIRUS REACTIVATION; CHRONIC HEPATITIS B; COHORT ANALYSIS; DRUG EFFICACY; HEMATOLOGIC MALIGNANCY; HEPATITIS; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; INCIDENCE; META ANALYSIS (TOPIC); MORBIDITY; MORTALITY; NONHUMAN; PROBABILITY; RETROSPECTIVE STUDY; RISK REDUCTION; SOLID TUMOR; SYSTEMATIC REVIEW (TOPIC); TREATMENT OUTCOME; VIRUS REACTIVATION; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL (TOPIC); DRUG EFFECTS; HOST PATHOGEN INTERACTION; META ANALYSIS; PHYSIOLOGY; VIROLOGY; VIRUS ACTIVATION;

ADENINE; ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS; CONTROLLED CLINICAL TRIALS AS TOPIC; GUANINE; HEPATITIS B; HEPATITIS B VIRUS; HOST-PATHOGEN INTERACTIONS; HUMANS; LAMIVUDINE; ORGANOPHOSPHONATES; THYMIDINE; VIRUS ACTIVATION;

EID: 84971519421     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.8907     Document Type: Article

References (65)

1. Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine. 2012; 30:2212-2219
2. Lin GN, Peng JW, Xiao JJ, Liu DY, Xia ZJ. Hepatitis B virus reactivation in hepatitis B surface antigen seropositive patients with metastatic non-small cell lung cancer receiving cytotoxic chemotherapy: the efficacy of preemptive lamivudine and identification of risk factors. Med Oncol. 2014; 31:119
3. Kim SJ, Hsu C, Song YQ, Tay K, Hong XN, Cao J, Kim JS, Eom HS, Lee JH, Zhu J, Chang KM, Reksodiputro AH, Tan D, et al. Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: analysis from the Asia Lymphoma Study Group. Eur J Cancer. 2013; 49:3486-3496
4. Lee GW, Ryu MH, Lee JL, Oh S, Kim E, Lee JH, Kim SB, Kim SW, Suh C, Lee KH, Kim WK, Lee JS, Kang YK. The prophylactic use of lamivudine can maintain doseintensity of adriamycin in hepatitis-B surface antigen (HBs Ag)-positive patients with Non-Hodgkin's lymphoma who receive cytotoxic chemotherapy. J Korean Med Sci. 2003; 18:849-854
5. Nagamatsu H, Itano S, Nagaoka S, Akiyoshi J, Matsugaki S, Kurogi J, Tajiri N, Yamasaki S, Koga H, Torimura T, Kumashiro R, Sata M. Prophylactic lamivudine administration prevents exacerbation of liver damage in HBe antigen positive patients with hepatocellular carcinoma undergoing transhepatic arterial infusion chemotherapy. Am J Gastroenterol. 2004; 99:2369-2375
6. Lau GK, Yiu HH, Fong DY, Cheng HC, Au WY, Lai LS, Cheung M, Zhang HY, Lie A, Ngan R, Liang R. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology. 2003; 125:1742-1749
7. Lee HJ, Kim DY, Keam B, Lee JH, Han SW, Oh DY, Yoon JH, Kim TY, Kim YJ, Lee KW, Kim JW, Jeong SH, Lee JS, et al. Lamivudine prophylaxis for hepatitis B virus carrier patients with breast cancer during adjuvant chemotherapy. Breast cancer. 2014; 21:387-393
8. Jang JW, Choi JY, Bae SH, Yoon SK, Chang UI, Kim CW, Cho SH, Han JY, Lee YS. A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo-lipiodolization. Hepatology. 2006; 43:233-240
9. Liaw YF, Kao JH, Piratvisuth T, Chan HLY, Chien RN, Liu CJ, Gane E, Locarnini S, Lim SG, Han KH, Amarapurkar D, Cooksley G, Jafri W, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: A 2012 update. Hepatol Int. 2012; 6:531-561
10. Huang H, Li X, Zhu J, Ye S, Zhang H, Wang W, Wu X, Peng J, Xu B, Lin Y, Cao Y, Li H, Lin S, et al. Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: a randomized clinical trial. JAMA. 2014; 312:2521-2530
11. Chen MY, Liu CJ, Kao JH. Prophylaxis nucleot(s) ides in chronic hepatitis B infected patients undergoing chemotherapy for malignancies. Hepatol Int. 2013; 7: S226-S227
12. Hsu C, Hsiung CA, Su IJ, Hwang WS, Wang MC, Lin SF, Lin TH, Hsiao HH, Young JH, Chang MC, Liao YM, Li CC, Wu HB, et al. A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: a randomized trial. Hepatology. 2008; 47:844-853
13. Long M, Jia W, Li S, Jin L, Wu J, Rao N, Feng H, Chen K, Deng H, Liu F, Su F, Song E. A single-center, prospective and randomized controlled study: Can the prophylactic use of lamivudine prevent hepatitis B virus reactivation in hepatitis B s-antigen seropositive breast cancer patients during chemotherapy? Breast Cancer Res Treat. 2011; 127:705-712
14. Ho EY, Yau T, Rousseau F, Heathcote EJ, Lau GK. Preemptive adefovir versus lamivudine for prevention of hepatitis B reactivation in chronic hepatitis B patients undergoing chemotherapy. Hepatol Int. 2015; 9:224-230
15. Lim LL, Wai CT, Lee YM, Kong HL, Lim R, Koay E, Lim SG. Prophylactic lamivudine prevents hepatitis B reactivation in chemotherapy patients. Aliment Pharmacol Ther. 2002; 16:1939-1944
16. Persico M, De Marino F, Russo GD, Morante A, Rotoli B, Torella R, De Renzo A. Efficacy of lamivudine to prevent hepatitis reactivation in hepatitis B virus-infected patients treated for non-Hodgkin lymphoma. Blood. 2002; 99:724-725
17. Leaw SJ, Yen CJ, Huang WT, Chen TY, Su WC, Tsao CJ. Preemptive use of interferon or lamivudine for hepatitis B reactivation in patients with aggressive lymphoma receiving chemotherapy. Ann Hematol. 2004; 83:270-275
18. Jia J, Lin F. [Lamivudine therapy for prevention of chemotherapy-induced reactivation of hepatitis B virus]. Chin J Hepatol. 2004; 12:628-629
19. Ozguroglu M, Bilici A, Turna H, Serdengecti S. Reactivation of hepatitis B virus infection with cytotoxic therapy in non-Hodgkin's lymphoma. Med Oncol. 2004; 21:67-72
20. Lim ST, Fei G, Quek R, Lim LC, Lee LH, Yap SP, Loong S, Tao M. The relationship of hepatitis B virus infection and non-Hodgkin's lymphoma and its impact on clinical characteristics and prognosis. Eur J Haematol. 2007; 79:132-137
21. Chen Y, Xu LP, Liu KY, Liu DH, Han W, Chen H, Zhang YC, Chen YH, Huang XJ. [A clinical study of allo-hematopoietic stem cell transplantation in HBsAg positive leukemia]. Chin J Intern Med. 2008; 47:316-319
22. Tsutsumi Y, Yamamoto Y, Tanaka J, Asaka M, Imamura M, Masauzi N. Prevention of hepatitis B virus reactivation under rituximab therapy. Immunotherapy. 2009; 1:1053-1061
23. Eren OO, Artac M, Boruban MC, Yavas O, Arslan U, Basaranoglu M. Chemotherapy-induced Hepatitis B virus reactivation in HbsAg positive cancer patients: a single center experience. Med Oncol. 2009; 26:386-392
24. Yeo W, Chan TC, Leung NW, Lam WY, Mo FK, Chu MT, Chan HL, Hui EP, Lei KI, Mok TS, Chan PK. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol. 2009; 27:605-611
25. Koo YX, Tan DS, Tan IB, Tao M, Chow WC, Lim ST. Hepatitis B virus reactivation and role of antiviral prophylaxis in lymphoma patients with past hepatitis B virus infection who are receiving chemoimmunotherapy. Cancer. 2010; 116:115-121
26. Topcuoglu P, Soydan E, Idilman R, Arslan O, Ozcan M, Ilhan O, Beksac M, Arat M, Gurman G. Allogeneic hematopoetic cell transplantation in patients positive for hepatitis B surface antigen. Biol Blood Marrow Transplant. 2010; 16:S288
27. Pei SN, Chen CH, Lee CM, Wang MC, Ma MC, Hu TH, Kuo CY. Reactivation of hepatitis B virus following rituximab-based regimens: a serious complication in both HBsAg-positive and HBsAg-negative patients. Ann Hematol. 2010; 89:255-262
28. Sohn BS, Ahn JH, Jung KH, Ahn SH, Son BH, Gong G, Kim SB. Updated longitudinal data on acute exacerbation of chronic hepatitis B in patients with breast cancer receiving anthracycline-based adjuvant chemotherapy: therapeutic vs. pre-emptive use of lamivudine. Jpn J Clin Oncol. 2011; 41:1059-1066
29. Yun J, Kim KH, Kang ES, Gwak GY, Choi MS, Lee JE, Nam SJ, Yang JH, Park YH, Ahn JS, Im YH. Prophylactic use of lamivudine for hepatitis B exacerbation in post-operative breast cancer patients receiving anthracycline-based adjuvant chemotherapy. Br J Cancer. 2011; 104:559-563
30. Yan Y, Zhang JW, Zhao HY, Huang Y, Hu ZH, Zhang L. [Retrospective analysis of the correlation between"hepatitis B virus infection and chemotherapy-induced hepatic injury in patients with lung cancer]. Chin J Clin Oncol. 2012; 39:465-469
31. Mya DH, Han ST, Linn YC, Hwang WY, Goh YT, Tan DC. Risk of hepatitis B reactivation and the role of novel agents and stem-cell transplantation in multiple myeloma patients with hepatitis B virus (HBV) infection. Ann Oncol. 2012; 23:421-426
32. Chen XQ, Peng JW, Lin GN, Li M, Xia ZJ. The effect of prophylactic lamivudine on hepatitis B virus reactivation in HBsAg-positive patients with diffuse large B-cell lymphoma undergoing prolonged rituximab therapy. Med Oncol. 2012; 29:1237-1241
33. Wang YH, Fan L, Wang L, Zhang R, Xu J, Fang C, Li JY, Xu W. Efficacy of prophylactic lamivudine to prevent hepatitis B virus reactivation in B-cell lymphoma treated with rituximab-containing chemotherapy. Support Care Cancer. 2013; 21:1265-1271
34. Nishida T, Hiramatsu N, Mizuki M, Nagatomo I, Kida H, Tazumi K, Shinzaki S, Miyazaki M, Yakushijin T, Tatsumi T, Iijima H, Kiso S, Kanto T, et al. Managing hepatitis B virus carriers with systemic chemotherapy or biologic therapy in the outpatient clinic. Hepatol Res. 2013; 43:339-346
35. Chen FW, Coyle L, Jones BE, Pattullo V. Entecavir versus lamivudine for hepatitis B prophylaxis in patients with haematological disease. Liver Int 2013; 33:1203-1210
36. Li HR, Huang JJ, Guo HQ, Zhang X, Xie Y, Zhu HL, Zhai LZ, Pu XX, Huang Y, Guo CC, Lin TY. Comparison of entecavir and lamivudine in preventing hepatitis B reactivation in lymphoma patients during chemotherapy. J Viral Hepat. 2011; 18:877-883
37. Min YW, Kim NJ, Gwak GY, Paik YH, Choi MS, Koh KC, Paik SW, Yoo BC, Lee JH. Lamivudine versus entecavir for prevention of hepatitis B virus reactivation in hepatitis B surface antigen positive non-hepatic cancer patients receiving chemotherapy. Hepatology. 2012; 56:387A-388A
38. Ling WH, Soe PP, Pang AS, Lee SC. Hepatitis B virus reactivation risk varies with different chemotherapy regimens commonly used in solid tumours. Br J Cancer. 2013; 108:1931-1935
39. Lau GK, He ML, Fong DY, Bartholomeusz A, Au WY, Lie AK, Locarnini S, Liang R. Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation. Hepatology. 2002; 36:702-709
40. Li YH, He YF, Jiang WQ, Wang FH, Lin XB, Zhang L, Xia ZJ, Sun XF, Huang HQ, Lin TY, He YJ, Guan ZZ. Lamivudine prophylaxis reduces the incidence and severity of hepatitis in hepatitis B virus carriers who receive chemotherapy for lymphoma. Cancer. 2006;106:1320-1325
41. Hsiao LT, Chiou TJ, Liu JH, Chu CJ, Lin YC, Chao TC, Wang WS, Yen CC, Yang MH, Tzeng CH, Chen PM. Extended lamivudine therapy against hepatitis B virus infection in hematopoietic stem cell transplant recipients. Biol Blood Marrow Transplant. 2006; 12:84-94
42. Cil T, Altintas A, Pasa S, Bayan K, Ozekinci T, Isikdogan A. Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis-B surface antigen (HBSAG) seropositive cancer patients undergoing cytotoxic chemotherapy. Leuk Lymphoma. 2008; 49:939-947
43. Huang H, Cai Q, Lin T, Lin X, Liu Y, Gao Y, Peng R. Lamivudine for the prevention of hepatitis B virus reactivation after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for patients with advanced or relapsed non-Hodgkin's lymphoma single institution experience. Expert Opin Pharmacother. 2009; 10:2399-2406
44. Shibolet O, Ilan Y, Gillis S, Hubert A, Shouval D, Safadi R. Lamivudine therapy for prevention of immunosuppressiveinduced hepatitis B virus reactivation in hepatitis B surface antigen carriers. Blood. 2002; 100:391-396
45. Idilman R, Arat M, Soydan E, Toruner M, Soykan I, Akbulut H, Arslan O, Ozcan M, Turkyilmaz AR, Bozdayi M, Karayalcin S, Van Thiel DH, Ozden A, et al. Lamivudine prophylaxis for prevention of chemotherapy-induced hepatitis B virus reactivation in hepatitis B virus carriers with malignancies. J Viral Hepat. 2004;11:141-147
46. Tsai SH, Dai MS, Yu JC, Ho CL, Chen YC, Wu YY, Chang PY, Kao WY, Chao TY. Preventing chemotherapyinduced hepatitis B reactivation in breast cancer patients: a prospective comparison of prophylactic versus deferred preemptive lamivudine. Supportive care cancer. 2011; 19:1779-1787
47. Gentile G, Russo E, De Angelis F, Di Rocco A, Fama A, Micozzi A, Pulsoni A, Martelli M, Mauro FR, Iori AP, Petrucci T, Vitale A, Antonelli G, et al. Efficacy and safety of long term tenofovir in high risk patients with hematological malignancies (HM) to prevent Hepatitis B Virus (HBV) reactivation after immunosuppressive therapies in real life. Hepatology. 2014; 60:1008A
48. Yeo W, Chan PK, Ho WM, Zee B, Lam KC, Lei KI, Chan AT, Mok TS, Lee JJ, Leung TW, Zhong S, Johnson PJ. Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy. J Clin Oncol. 2004; 22:927-934
49. Yeo W, Ho WM, Hui P, Chan PK, Lam KC, Lee JJ, Johnson PJ. Use of lamivudine to prevent hepatitis B virus reactivation during chemotherapy in breast cancer patients. Breast Cancer Res Treat. 2004; 88:209-215
50. Dai MS, Chao TY, Kao WY, Shyu RY, Liu TM. Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP. Ann Hematol. 2004; 83:769-774
51. Yeo W, Hui EP, Chan AT, Ho WM, Lam KC, Chan PK, Mok TS, Lee JJ, Mo FK, Johnson PJ. Prevention of hepatitis B virus reactivation in patients with nasopharyngeal carcinoma with lamivudine. Am J Clin Oncol. 2005; 28:379-384
52. Hui CK, Cheung WW, Au WY, Lie AK, Zhang HY, Yueng YH, Wong BC, Leung N, Kwong YL, Liang R, Lau GK. Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapy. Gut. 2005; 54:1597-1603
53. Choi J, An J, Shim JH, Kim H-D, Ha Y-J, Jun M-J, Yang YJ, Lee SB, Ae Kim G, Yang JE, Park EJ, Lee D, Kim KM, et al. Risk and Prediction of Hepatitis B Reactivation in Inactive Carriers Receiving Pre-emptive Antiviral Therapy During Cancer Chemotherapy: 1853. [Abstract]. Hepatology October. 2014; 60:1088A-1089A
54. Yoo JJ, Kim HY, Lee JH, Yu SJ, Kim YJ, Yoon JH, Lee HS. Comparison of lamivudine, telbivudine, and entecavir as antiviral prophylaxis for patients with Hepatitis B undergoing cytotoxic chemotherapy. Hepatology. 2012; 56:631A
55. Xunrong L, Yan AW, Liang R, Lau GK. Hepatitis B virus (HBV) reactivation after cytotoxic or immunosuppressive therapy-pathogenesis and management. Rev Med Virol. 2001; 11:287-299
56. Loomba R, Rowley A, Wesley R, Liang TJ, Hoofnagle JH, Pucino F, Csako G. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med. 2008; 148:519-528
57. Perrillo RP, Gish R, Falck-Ytter YT. American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology. 2015; 148:221-244
58. Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, Ioannidis JP, Straus S, Thorlund K, Jansen JP, Mulrow C, Catala-Lopez F, Gotzsche PC, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015; 162:777-784
59. Kohrt HE, Ouyang DL, Keeffe EB. Systematic review: lamivudine prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection. Aliment Pharmacol Ther. 2006; 24:1003-1016
60. Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JA. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011; 343:d5928
61. Zhou YY, Zhu GQ, Wang Y, Zheng JN, Ruan LY, Cheng Z, Hu B, Fu SW, Zheng MH. Systematic review with network meta-analysis: statins and risk of hepatocellular carcinoma. Oncotarget. 2016. doi: 10.18632/oncotarget.7832
62. Zhu GQ, Shi KQ, Huang GQ, Wang LR, Lin YQ, Braddock M, Chen YP, Zhou MT, Zheng MH. A network meta-analysis of the efficacy and side effects of udca-based therapies for primary sclerosing cholangitis. Oncotarget. 2015; 6: 26757-26769. doi: 10.18632/oncotarget.5610
63. Zhu GQ, Shi KQ, Huang S, Wang LR, Lin YQ, Huang GQ, Chen YP, Braddock M, Zheng MH. Systematic review with network meta-analysis: the comparative effectiveness and safety of interventions in patients with overt hepatic encephalopathy. Aliment Pharmacol Ther. 2015; 41: 624-635
64. Zhu GQ, Shi KQ, Yu HJ, He SY, Braddock M, Zhou MT, Chen YP, Zheng MH. Optimal adjuvant therapy for resected hepatocellular carcinoma: a systematic review with network meta-analysis. Oncotarget. 2015; 6:18151-18161. doi: 10.18632/oncotarget.4098
65. Zhu GQ, Zou ZL, Zheng JN, Chen DZ, Zou TT, Shi KQ, Zheng MH. Systematic Review and Network Meta-Analysis of Randomized Controlled Trials: Comparative Effectiveness and Safety of Direct-Acting Antiviral Agents for Treatment-Naive Hepatitis C Genotype 1. Medicine. 2016; 95:e3004